Benitec Biopharma (BNTC) 8-K furnishes results for Sept 30, 2025

Rhea-AI Filing Summary

FAQ

8-K Event Classification

What did Benitec Biopharma (BNTC) announce in its 8-K?

Which item of the 8-K covers BNTC’s results disclosure?

Is the information in Exhibit 99.1 considered filed?

Will the Exhibit 99.1 press release be incorporated by reference?

Where do BNTC shares trade and under what ticker?

What exhibit contains the press release details?

Benitec Biopharma Inc. (BNTC) filed an 8‑K stating it furnished a press release with financial results for the fiscal quarter ended September 30, 2025, and an operational update.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Benitec Biopharma Inc. (BNTC) filed an 8‑K stating it furnished a press release with financial results for the fiscal quarter ended September 30, 2025, and an operational update. The press release is attached as Exhibit 99.1.

The company notes the information furnished under Item 2.02, including Exhibit 99.1, is not deemed filed for liability purposes and is not incorporated by reference unless expressly stated. BNTC’s common stock trades on The Nasdaq Stock Market LLC.

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

It furnished a press release with financial results for the quarter ended September 30, 2025, and provided an operational update as Exhibit 99.1.

Item 2.02 covers the disclosure of financial results furnished via Exhibit 99.1.

No. The information furnished under Item 2.02, including Exhibit 99.1, is not deemed filed for purposes of Section 18.

It will not be incorporated by reference unless expressly incorporated by specific reference in a future filing.

BNTC common stock trades on The Nasdaq Stock Market LLC under the symbol BNTC.

BENITEC BIOPHARMA INC.

Date: November 14, 2025

/s/ Jerel A. Banks

Dr. Jerel A. Banks

Chief Executive Officer

Exhibit 99.1 contains the press release dated November 14, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/14/2025 - 05:31 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

BENITEC BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39267

84-4620206

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


3940 Trust Way, Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 780-0819

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	BNTC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On November 14, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

99.1		Press Release of Benitec Biopharma Inc. dated November 14, 2025

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Source: View Original Filing on SEC EDGAR